Biodesix Inc Revenue Growth Rates (BDSX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biodesix Inc   (NASDAQ: BDSX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

BDSX's Revenue Growth by Quarter and Year

Biodesix Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BDSX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 26.86
1st Quarter March 25.56
FY 52.42

BDSXs Annual Revenue
Biodesix Inc 's Revenue in the fiscal year 2025 $ 88.50 millions
Biodesix Inc 's Revenue in the fiscal year 2024 $ 71.32 millions
Biodesix Inc 's Revenue in the fiscal year 2023 $ 49.09 millions
Biodesix Inc 's Revenue in the fiscal year 2022 $ 38.21 millions
Biodesix Inc 's Revenue in the fiscal year 2021 $ 54.51 millions




BDSX Revenue second quarter 2026 Y/Y Growth Comment
Biodesix Inc achieved in the second quarter 2026, above Company average Revenue growth of 34.17% year on year, to $ 26.86 millions.

Looking into second quarter 2026 results within Medical Laboratories industry 22 other companies have achieved higher Revenue growth. While Biodesix Inc ' s Revenue rise of 34.17% ranks overall at the positon no. 2322 in the second quarter 2026.


BDSX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 40.77 % 39.26 % 52.65 %
3rd Quarter September - 19.94 % 34.54 % 21.42 %
2nd Quarter June 34.17 % 11.66 % 51.05 % 8.4 %
1st Quarter March 42.32 % 21.19 % 63.58 % 38.32 %
FY   - 24.09 % 45.3 % -

Financial Statements
Biodesix Inc 's second quarter 2026 Revenue $ 26.86 millions BDSX's Income Statement
Biodesix Inc 's second quarter 2025 Revenue $ 20.02 millions Quarterly BDSX's Income Statement


BDSX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 32.11 % 12.56 % 8.75 %
3rd Quarter September - 8.74 % 1.23 % 13.65 %
2nd Quarter June 5.09 % 11.47 % 20.99 % 31.02 %
1st Quarter March -11.13 % -12.09 % 1.02 % -5.72 %
FY (Year on Year)   - 24.09 % 45.3 % -


Back to BDSX Growth rate Comparisons >> Back to BDSX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #336
Overall #2322

Revenue Y/Y Growth Statistics
High Average Low
127.15 % 23.79 % -59.4 %
(Jun 30 2021)   (Jun 30 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #336
Overall #2322
Revenue Y/Y Growth Statistics
High Average Low
127.15 % 23.79 % -59.4 %
(Jun 30 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biodesix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
422.83 % 26.62 % -75.27 %
(Dec 31 2019)  


BDSX's II. Quarter Q/Q Revenue Comment
Biodesix Inc achieved in the II. Quarter 2026 below company average Revenue increase of 5.09% quarter on quarter, to $ 26.86 millions.

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Biodesix Inc 's Revenue growth quarter on quarter, overall rank is 1140.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #168
Overall #1140
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #168
Overall #1140
Revenue Q/Q Growth Statistics
High Average Low
422.83 % 26.62 % -75.27 %
(Dec 31 2019)  


BDSX's II. Quarter Q/Q Revenue Comment
Biodesix Inc achieved in the II. Quarter 2026 below company average Revenue increase of 5.09% quarter on quarter, to $ 26.86 millions.

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Biodesix Inc 's Revenue growth quarter on quarter, overall rank is 1140.


Biodesix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 102.94 $ 96.10 $ 88.50 $ 80.17 $ 76.56
Y / Y Revenue Growth (TTM) 34.46 % 29.05 % 24.08 % 22.29 % 25.7 %
Year on Year Revenue Growth Overall Ranking # 656 # 364 # 160 # 139 # 119
Seqeuential Revenue Change (TTM) 7.12 % 8.58 % 10.39 % 4.72 % 2.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 2322 # 1789 # 968 # 958 # 676


Cumulative Revenue growth Comment
Biodesix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.46% year on year, to $ 103 millions if the fiscal year would have ended in Jun 30 2026.
Biodesix Inc 's trailing twelve months Revenue growth was higher than company's average 23.79% and higher than 29.05% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 7.12 % from $96.1 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at23.79%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.12 % increase from $96.1 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 364 to 656.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 138
Overall # 656

Revenue TTM Y/Y Growth Statistics
High Average Low
127.15 %
 23.79 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2322
Cumulative Revenue growth Comment
Biodesix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.46% year on year, to $ 103 millions if the fiscal year would have ended in Jun 30 2026.
Biodesix Inc 's trailing twelve months Revenue growth was higher than company's average 23.79% and higher than 29.05% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 7.12 % from $96.1 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at23.79%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.12 % increase from $96.1 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 364 to 656.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 138
Overall # 656

Revenue TTM Y/Y Growth Statistics
High Average Low
127.15 %
23.79 %
-59.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2322




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BDSX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions


About Biodesix Inc Revenue Growth Rates (BDSX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biodesix Inc (CIK 1439725).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-335036
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biodesix Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.